Results 11 to 20 of about 15,210 (229)
TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS [PDF]
Mediterranean Journal of Hematology and Infectious Diseases, 2017 In 2002, the WHO classification reduced the proportion of blasts in the bone marrow (BM) necessary for the diagnosis of acute myeloid leukemia (AML) from 30% to 20%, eliminating the RAEB-t subtype of myelodysplastic syndromes (MDS).
Eleonora De Bellis +11 more
doaj +5 more sources
Differential Histone Posttranslational Modifications Induced by DNA Hypomethylating Agents [PDF]
Cancer Control, 2022 Introduction The prototype DNA hypomethylating agents 5-azacytidine (5AC) and decitabine (DAC) are currently FDA-approved for treatment of blood and bone marrow disorders like myelodysplastic syndrome.
Sridhar A Malkaram +7 more
doaj +3 more sources
Meta-analysis on hypomethylating agents in myelodysplastic syndromes
Haematologica, 2010 The addition of hypomethylating agents into the armatorium against myelodysplastic syndromes (MDS) is commonly accepted as a promising new therapeutic option in this otherwise frustrating field.
Christine Herbst +2 more
doaj +3 more sources
Clinical update on hypomethylating agents [PDF]
International Journal of Hematology, 2019 Hypomethylating agents (HMAs), azacitidine and decitabine, are standards of care in higher-risk myelodysplastic syndromes and in acute myeloid leukemia patients ineligible for intensive therapy. Over the last 10 years, research efforts have sought to better understand their mechanism of action, both at the molecular and cellular level.
Matthieu, Duchmann, Raphael, Itzykson
openaire +2 more sources
Mitoxantrone—A Hypomethylating Agent? [PDF]
Cancer Biology & Therapy, 2003 Commentary to: Mitoxantrone Mediates Demethylation and Re-Expression of Cyclin D2, Estrogen Receptor 14.3.3 Sigma In Breast Cancer Cells Belinda S. Parker, Suzanne M. Cutts, Abraham Nudelman, Ada Rephaeli, Don R.
Allen S. Yang, Jean-Pierre J. Issa
openaire +1 more source
Mediterranean Journal of Hematology and Infectious Diseases, 2016 Objectives: Low-dose cytarabine (LD-AraC) is still regarded as the standard of care in elderly patients with acute myeloid leukemia (AML) ‘unfit’ for intensive chemotherapy.
Maël Heiblig +12 more
doaj +1 more source
DNA methylation at tobacco telomeric sequences [PDF]
, 2011 Majerová et al. (Plant Mol Biol, 2011) have recently reported that a considerable fraction of cytosines at tobacco telomeres is methylated. Although the data presented in this report indicate that tobacco telomeric sequences undergo certain levels of DNA
Vaquero Sedas, María Isabel +1 more
core +1 more source
Hypomethylating agents after allogeneic blood stem cell transplantation [PDF]
Stem Cell Investigation, 2016 Allogeneic blood stem cell transplantation (allo-SCT) is a potentially curative treatment for patients with myeloid malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), but relapse remains the major cause of treatment failure. So far, therapeutic options for patients with AML or MDS who relapse after allo-SCT generally
Thomas, Schroeder +3 more
openaire +2 more sources
Acta Medica Bulgarica, 2020 Introduction: Hypomethylating agents have become a standard therapy for certain myeloid malignancies.
Varbanova V. +9 more
doaj +1 more source
Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors. [PDF]
, 2014 BackgroundIn 31 solid tumor patients treated with the demethylating agent decitabine, we performed tumor biopsies before and after the first cycle of decitabine and used immunohistochemistry (IHC) to assess whether decitabine increased expression of ...
A Kumari +55 more
core +2 more sources